Could a drug boost chemo for tough bone cancer?

NCT ID NCT03643133

Ongoing Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding mifamurtide to standard chemotherapy helps people with high-risk osteosarcoma, a type of bone cancer. The study includes 60 patients aged 2 to 50 with newly diagnosed, aggressive disease. Researchers will compare survival and relapse rates between those who get mifamurtide plus chemo and those who get chemo alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mifamurtide (MEPACT)
What this could lead to: If it works, this could point toward a more effective treatment for high-risk osteosarcoma, potentially improving survival rates.
What could go wrong: This is a small, early-phase trial with only 60 participants. The drug may not improve outcomes and could cause side effects like fever or fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasms, Bone Tissue osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOSARCOMA

Contacts and locations

Locations

CHRU de Nancy - Onco-hématologie pédiatrique

Vandœuvre-lès-Nancy, France
CHU Amiens-Picardie - Service d'oncologie hématologie pédiatrique

Amiens, France
CHU Arnaud de Villeneuve - Onco-hématologie pédiatrique

Montpellier, France
CHU Bretonneau - Service d'oncologie médicale

Tours, France
CHU Toulouse - Hôpital des Enfants - Service d'Hémato-Immuno-Oncologie

Toulouse, France
CHU d'Angers - Service d'oncologie pédiatrique

Angers, France
CHU de Caen - Service d'oncologie hématologie pédiatrique

Caen, France
CHU de Grenoble - Service d'oncologie hématologie pédiatrique

La Tronche, France
CHU de Nantes - Service d'oncologie hématologie pédiatrique

Nantes, France
CHU de Nice - Service d'oncologie hématologie pédiatrique

Nice, France
Centre Eugène Marquis - Service d'oncologie médicale

Rennes, France
Centre Léon Bérard - IHOPE

Lyon, France
Centre Léon Bérard - Service d'oncologie médicale

Lyon, France
Centre Oscar Lambret - Unité d'onco-pédiatrie

Lille, France
Hôpital Armand Trousseau - Service d'hématologie et d'oncologie pédiatrique

Paris, France
Hôpital Charles Nicolle - Hémato-Immuno-Oncologie Pédiatrique

Rouen, France
Hôpital Clocheville - Hématologie et oncologie pédiatrique

Tours, France
Hôpital Cochin

Paris, France
Hôpital Hautepierre - Onco-hématologie pédiatrique

Strasbourg, France
Hôpital de Hautepierre - Onco-hématologie adulte

Strasbourg, France
Hôpital de la Timone - Service d'oncologie pédiatrique

Marseille, France
Hôpital de la Timone - service d'oncologie médicale

Marseille, France
Institut Bergonié - Service d'oncologie médicale

Bordeaux, France
Institut Claudius Regaud - service d'oncologie médicale

Toulouse, France
Institut Curie - Service d'oncologie médicale

Paris, 75000, France
Institut Curie - Service d'oncologie pédiatrique

Paris, France
Institut Gustave Roussy - Service d'oncologie médicale

Villejuif, France
Institut Gustave Roussy - Service de cancérologie de l'enfant et de l'adolescent

Villejuif, 94800, France
Institut de Cancérologie de Lorraine - Service d'oncologie médicale

Vandœuvre-lès-Nancy, France
Institut de Cancérologie de l'Ouest (Site René Gauducheau) - Service d'oncologie médicale

Saint-Herblain, France
Institut régional du Cancer de Montpellier - Service d'oncologie médicale

Montpellier, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.